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Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by 
Palladium-Functionalized Microdevices 
Catherine Adam,[a] Ana M. Pérez-López,[a] Lloyd Hamilton,[b] Belén Rubio-Ruiz,[a] Thomas L. Bray,[a] 
Dirk Sieger,[b],[a] Paul M. Brennan*[a],[c] and Asier Unciti-Broceta*[a] 
 
Abstract: SN-38, the active metabolite of irinotecan, is released upon 
liver hydrolysis to mediate potent antitumor activity. Systemic 
exposure to SN-38, however, also leads to serious side effects. To 
reduce systemic toxicity by controlling where and when SN-38 is 
generated, a new prodrug was specifically designed to be 
metabolically stable and undergo rapid Palladium-mediated activation. 
Blocking the phenolic OH of SN-38 with a 2,6-bis(propargyloxy)benzyl 
group led to significant reduction of cytotoxic activity (up to 44-fold). 
Anticancer properties were swiftly restored in the presence of 
heterogeneous Palladium (Pd) catalysts to kill colorectal cancer and 
glioma cells, proving the efficacy of this novel masking strategy for 
aromatic hydroxyls. Combination with a Pd-activated 5FU prodrug 
augmented the antiproliferative potency of the treatment, while 
displaying no activity in the absence of the Pd source, which illustrates 
the benefit of achieving controlled release of multiple approved 
therapeutics —sequentially or simultaneously— by the same 
bioorthogonal catalyst to increase anticancer activity. 
Introduction 
Bioorthogonal reactions are designed to take place in cells and 
organisms without interfering with biological functions.[1] In the 
pursuit of exploiting such processes in cancer therapy, reactions 
and tools that were once exclusively used to synthesize drugs in 
chemistry labs have been recently adapted to perform such tasks 
in living systems.[2-20] Chemotherapeutics as doxorubicin,[2-7] 
5FU,[8-11] gemcitabine,[17] floxuridine,[18] vorinostat[19] or nitric oxide 
precursors[20] can be “manufactured” from inactive precursors in 
biological environments through a variety of bio-independent 
processes, including click-to-release reactions and bioorthogonal 
organometallic catalysis. In combination with a suitable cancer 
targeting strategy (e.g. antibody-based tumor targeting,[15] 
enhanced permeability and retention effect,[6,11] intratumoral 
implantation[7]), these highly selective reactions can facilitate the 
spatially controlled release of one or more therapeutic agents to 
localize drug activity at the tumor site. While such approaches are 
yet to demonstrate its utility in the clinic, they have the potential 
to reduce systemic side effects and enhance treatment efficacy 
by generating greater drug levels at the disease site than can be 
safely achieved by standard chemotherapy. 
Palladium (Pd) catalysts are one of the tools of choice currently 
under investigation to release caged drugs in vitro and in vivo.[7-
11,17-20] The selection of this metal is based on its high bio-
compatibility, its versatility to adopt different shapes and sizes and 
its remarkable capabilities to catalyze N- and O-dealkylation 
reactions on manifold types of substrates under physiological 
conditions.[21-23] Our lab is currently investigating the application 
of heterogeneous Pd catalysts as implantable devices to mediate 
drug release with spatiotemporal control and in a catalytic fashion, 
with the goal of improving the safety profile of chemotherapies 
without having the short, limited life of other local therapy 
modalities such as drug eluting devices (carmustine wafers)[24] or 
brachytherapy.[25]  
The camptothecin-derived topoisomerase I inhibitors topotecan 
and irinotecan (Figure 1a) are anticancer drugs used in the 
treatment of ovarian (topotecan), lung (both) and colon 
(irinotecan) cancers. Irinotecan crosses the blood brain barrier[26] 
and displays high cytotoxic activity against glioblastoma cells with 
multi-drug resistance to other therapies.[27] In addition, several 
Phase II clinical trials have reported that the combination of 
bevacizumab and irinotecan shows promising activity in recurrent 
malignant glioma with a modest increment in median survival.[28-
30] The side effects of irinotecan treatments are, however, a major 
concern that limits its therapeutic dose and significantly impacts 
patient’s quality of life. To circumvent this issue, the intratumoral 
implantation of irinotecan-loaded drug-eluting beads has been 
investigated in patients with recurrent glioblastoma[31] and 
colorectal liver metastasis.[32] While these treatments are well 
tolerated, the drug is fully cleared from the organism within hours 
of implantation, thus reducing its anticancer effect.[31,32] Of note, 
irinotecan is in fact an orally-bioavailable prodrug that requires 
enzymatic conversion into its active metabolite SN-38 (1) to reach 
its full cytotoxic potential (Figure 1a).[33] Although glioma cells 
have been shown to partly metabolize irinotecan, the drug is 
primarily metabolized into 1 in the liver, from where it distributes 
throughout the organism. This further rationalizes the limited 
effect of irinotecan-loaded drug-eluting devices in the treatment of 
brain cancers. 
Building on previous success in the development and bio-
independent release of caged drugs with catalyst-loaded de-
vices,[7-11]  herein we report the design, synthesis and screening 
of a novel class of inactive camptothecin derivatives that are 
selectively converted into cytotoxic 1 by bioorthogonal Palladium 
chemistry.
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Figure 1. (a) Camptothecin and clinically approved derivatives topotecan and irinotecan. (b) Biological (enzymatic) activation of irinotecan to release the active 
metabolite 1 and bioorthogonal (palladium-catalyzed) activation of alkylated prodrugs of 1. (c) Dose-response curves for HCT116, U-87 and U-251 cells after 5 d 
treatment with 1, topotecan and irinotecan. Error bars: ± SEM, n = 3.
Results and Discussion 
Rationale for prodrug design and synthesis of 2a-d. 
Preliminary screening of the anticancer properties of 1, topotecan 
and irinotecan against colorectal cancer HCT116 cells, and 
glioma U-87 and U-251 cell lines, confirmed the superior potency 
of 1 relative to irinotecan (Figure 1c). Topotecan also has lower 
potency against the HCT116 cell line and, to a lesser extent, U-
251 when compared to 1 (Figure 1c), but the activity gap is not 
as prominent as in irinotecan, which has greater than 80-fold 
difference in EC50 (Table S1). Encouraged by the dramatic 
change in activity between compounds that only differ by the 
chemical group found around the C10 position of the 
camptothecin scaffold (ring A, Figure 1a), it was rationalized that 
the aromatic hydroxyl group of 1 was a convenient handle where 
bulky masking groups could be incorporated and thereby reduce 
prodrug-target interactions.  
It has been recently reported that the blockade of the NH2 group 
of doxorubicin with an o-(propargyloxy)benzyloxycarbonyl group 
dramatically reduces the bioactivity of the resulting derivative, 
while making it activatable by Pd chemistry.[7] Inspired on this 
observation, a novel masking group —namely 2,6-
bis(propargyloxy)benzyl— incorporating two symmetrically-
placed Pd-sensitive triggers was designed to block the OH at C10 
of 1 and thereby endow high metabolic stability and increased 
sensitivity to Pd catalysis. Upon catalyst-mediated O-dealkylation 
of either of the propargyl groups, the masking group will eliminate 
spontaneously to release 1 (see activation mechanism in 
Scheme 1b) Derivatives 2a and 2b, incorporating a propargyl and 
a 4-propargyloxybenzyl group, respectively, were used as 
positive controls. A 2,6-bis(methoxy)benzyl group was also tested 
as a steric mimic of the 2,6-bis(propargyloxy)benzyl group that is 
unable to be cleaved by Pd chemistry (negative control). 
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Prodrugs 2a-d were prepared in a single Williamson ether 
coupling of 1 and the corresponding alkyl halide in the presence 
of a base (Scheme 1). Commercially available propargyl bromide 
and 2,6-dimethylbenzyl chloride were used in the synthesis of 2a 
and 2d, respectively, and benzyl chlorides 5 and 9 were used (see 
Supp. Inf.) for the preparation of 2b and 2c. Of note, alkylation 
rates greatly increased under microwave irradiation.  
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Scheme 1. a) Synthesis prodrugs 2a-d. Reagents and conditions: (i) Alkyl halide, K2CO3, DMF, rt, overnight; or (ii) Alkyl halide, K2CO3, MeCN, µw, 120 ºC, 2 h. b) 
Proposed Pd-triggered uncaging mechanism of 2b,c. 
 
Cytotoxicity study: 1 vs 2a-d. The antiproliferative properties of 
compounds 2a-d were tested in cancer cell culture against 
HCT116, U-87 and U-251 cells and compared to 1. In line with the 
expectation that steric bulk around the phenol group at C10 
reduces compounds’ capacity to interact with its target 
(topoisomerase I),[34] it was found that the larger the alkyl group 
the greater the reduction in cytotoxicity (Fig. 2). O-propargylation 
(2a) of 1 slightly reduced cytotoxicity compared to the parent 
compound (up to 3-fold reduction, Table 1). Incorporation of a 4-
propargyloxybenzyl group (2b) had a superior while still minor 
effect (up to 9-fold reduction). In contrast, compound 2c 
(containing the novel 2,6-bis(propargyloxy)benzyl group) led to a 
much greater reduction in cytotoxicity across the three cell lines 
(up to 44-fold reduction) and, thus, was selected for the next 
phase of investigation. Control compound 2d also decreased the 
experimental cytotoxicity in all cell lines (Fig. S1) by a similar 
magnitude to 2c. EC50 values are shown in Table 1. 
 
 
Table 1. Calculated EC50 values (nM) for 1 and 2a-d in colorectal and glioma 
cell lines. n = 3. 
Compound HCT116 U-87 U-251 
1 1.9 94 5.8 
2a 5.1 63 12 
2b 16 123 22 
2c 84 1466 205 
2d 104 603 92 
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Figure 2. Dose response curves for HCT116, U-87 and U-251 cells after 5 d 
treatment with 1 or 2a-c. Error bars: ± SEM, n = 3. 
Prodrug Activation Studies: In Vitro and in Cell Culture. 
Prodrug 2c was incubated with 30 µm Tentagel resins loaded with 
Pd(0) nanoparticles (Pd-microdevices, 2 % w/w in Pd)[7] under 
physiological conditions to assess its sensitivity to Pd catalysis. 
Pd-microdevices were suspended in PBS with 10% v/v serum 
containing either 2c, 1 (+ve control) or 2d (–ve control) and 
incubated for 2 d at 37 ºC. Naked beads (used as purchased prior 
to Pd loading) were used as a metal-free control. Reactions were 
monitored by fluorescence spectroscopy. The characteristic 
emission spectrum of 1 (λmax= 547 nm, which is absent in 2c and 
2d) facilitated the study of drug release by fluorescence analysis. 
As shown in Figure 3b,c, fluorescence signal from uncaged 
compound 1 rapidly increased over time when 2c was incubated 
with Pd-microdevices, being patently visible after 4 h. In contrast, 
incubation of 2c alone (Figure S2) or with naked beads (Figure 
3d) under the same conditions did not increase the signal at 547 
nm (= no formation of 1). Similarly, incubation of the control 
compound 2d (Figure S3) with Pd-resins did not result in the 
release of 1. A decrease in the overall fluorescence intensity was 
observed both in the presence of Pd-microdevices and naked 
beads, presumably due to partial compound sequestration by the 
device. Incubation of unmodified 1 with Pd-microdevices or naked 
beads resulted in identical fluorescence spectra (Figure 3e), 
indicating that Pd does not have any effect on the structural 
integrity of the active drug 1. 
 
Figure 3. (a) Palladium catalyzed conversion of 2c into 1. (b,c) Rate of 
transformation of 2c (100 µM) into 1 in the presence of Pd(0) (1 mg/mL Pd-
devices) in PBS + 10% serum at 37 ºC. (b) Monitoring of changes in 
fluorescence spectra over time. (c) Increase of fluorescence intensity at 547 nm 
over time (d) Control experiment: fluorescence spectra of 2c (100 µM) after 2 d 
in biocompatible conditions in the presence of naked beads. Black line 
represents the fluorescent spectra of 1 (100 µM). (e) Control experiment: 
fluorescence spectra of 1 after 2 d in biocompatible conditions in the presence 
of Pd-devices (dotted line) or naked beads (solid line). 
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Figure 4. Pd-catalyzed uncaging of 2c in cancer cell culture. Experiments: 0.1% 
(v/v) DMSO (control, grey); 1 mg/mL of Pd-devices (–ve control, black stripes); 
1 (+ve control, orange); 2c (–ve control, green); 1 mg/mL of Pd-devices + 2c 
(activation assay, green with black stripes). Cell viability was measured at day 
5 using PrestoBlue. Error bars: ± SEM, n = 3. 
The bioorthogonal release of cytotoxic 1 from inactive 2c by 
extracellular Pd-microdevices was then tested in cancer cell 
culture in HCT116, U-87 and U-251 cells (Figure 4). Experiments 
were conducted under standard cell culture conditions (media 
supplemented with serum, 5% CO2, 37 °C). Cells were 
independently treated with Pd-microdevices (1 mg/mL) or 2c (–ve 
controls) or in combination (activation assay) and compared to 
treatment with unmodified 1 (+ve control) across a range of 
concentrations. As expected,[7-11] the devices (which are larger 
than cells and remain in the extracellular space) displayed no 
toxic effect. In contrast, the Pd-devices/2c combination led to 
potent antiproliferative effect in all cell lines, slightly lower than 
that mediated by direct treatment with 1. Due to the high potency 
of the active metabolite, nanomolar prodrug concentrations were 
sufficient to achieve high toxicity, while 2c did not display 
cytotoxicity in the absence of the Pd source. As expected, the 
antiproliferative properties of 2d were not improved in the 
presence of Pd-microdevices (see Figure S7). 
Multi prodrug activation study: Co-treatment with Pro-5FU. 
Irinotecan is typically administered in combination with 5FU for 
the treatment of colorectal cancer.[35] As our lab had previously 
developed a Pd-labile prodrug of 5FU, a.k.a. Pro-5FU (Figure 
5),[8] we were intrigued about the prospect of combining 2c and 
Pro-5FU in the presence of Pd to simultaneously release two 
clinically-used synergistic drugs by the same bioorthogonal 
triggering mechanism. Such an approach could serve to boost 
treatment efficacy without compromising safety, an optimal 
strategy for fighting difficult-to-treat cancers. Following the 
protocol described before, colorectal cancer HCT116 cells were 
incubated with 2c and Pro-5FU in the presence and absence of 
Pd-microdevices. The experiment was also performed in the U-
87 cell line, since the therapeutic effect mediated by the 2c/Pd-
devices combination was suboptimal (Figure 4). As shown in 
Figure 5, no signs of toxicity were observed from the combination 
of Pro-5FU (30 or 100 µM) and 2c (10 or 100 nM) in either cell 
line (see Figure S8 for co-treatment dose-response curves). 
Notably, in the presence of the activating device, the combined 
treatment of the prodrugs elicited superior cytotoxic activity than 
the 2c/Pd-devices or direct treatment with 1 (Figure 5); evidence 
that both drugs were concomitantly released by Pd chemistry. 
Preliminary assessment on the most effective timing of 
administration of the combination partners against U-87 cells 
suggested that compound 2c should be administered first (see 
Figure S9). The potential of manufacturing multiple synergistic 
drugs at a desired location is one of the most clinically relevant 
features of this strategy. 
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Figure 5. Combined Pd-catalyzed activation of 2c and Pro-5FU in cancer cell 
culture. Experiments: 0.1% (v/v) DMSO (control, grey); 1 mg/mL of Pd-devices 
(–ve control, black stripes); 1 mg/mL of Pd-devices + 2c (+ve control activation, 
green with black stripes); 1 + 5FU (+ve control, yellow); 2c + Pro-5FU (–ve 
control, light blue); 1 mg/mL of Pd-devices + 2c + Pro-5FU (combined activation 
assay, blue stripes). Cell viability was measured at day 5 using PrestoBlue. 
Error bars: ± SEM, n = 3. 
Conclusions 
In this manuscript we have reported the first inactive precursor of 
the potent topoisomerase I inhibitor SN-38 (1) that is specifically 
released by Pd chemistry. Prodrug 2c was successfully masked 
with a novel alkyl group, 2,6-bis(propargyloxy)benzyl, which 
incorporates two Pd-labile propargyl groups at the ortho positions 
of the benzyl group to increase steric hindrance and augment the 
rate of cleavage in the presence of Pd catalysts. 2c showed low 
inherent cytotoxicity to colorectal cancer and glioma cells. In the 
presence of extracellular Pd-microdevices, the Pd-labile group at 
the C10 position of the prodrug was efficiently cleaved to release 
the cytotoxic compound 1 both in vitro and in cancer cell culture. 
While previous attempts to make multiple bioactive agents in cell 
culture have been reported,[36] herein it is shown for the first time 
the concomitant uncaging of two drugs used in clinical 
combinations by the same bioorthogonal method. This study 
showcases the versatile applicability of using heterogeneous 
metal catalysts as a way to control the release of therapeutics at 
desired locations. By intratumoral implantation of the Pd-
devices,[7] otherwise toxic therapeutic agents such as 1 and 5FU 
could be generated at the tumor site to mediate focal 
chemotherapy and thereby reduce systemic side effects. 
Experimental Section 
General. Reactions requiring anhydrous conditions were carried out under 
nitrogen in oven-dried glassware. Dry solvents and reagents were 
purchased from Acros, Fluorochem, Sigma-Aldrich or VWR and used as 
received. Irinotecan was purchased from Carbosynth, and topotecan from 
ABCR. Both were used as purchased. NMR spectra were recorded on a 
Bruker 500 MHz spectrometer at 300 K and referenced relative to the 
solvent residual peaks with chemical shifts (δ) reported in ppm. Coupling 
constants (J) are reported in Hertz. High resolution mass spectra were 
measured in a Bruker MicrOTOF II. Analytical and semi-preparative TLC 
were performed using Merck TLC Silica Gel 60 F254 plates and visualized 
by UV light and flash column chromatography using silica gel (220−440 
mesh, Sigma-Aldrich). All compounds used in the biological experiments 
were >95% pure by UPLC, as measured using a C18 Column, 60 ºC; 
monitoring at 210 nm; eluent A, water with TFA (0.1%); eluent B, 
acetonitrile. Method 1 @0.4 mL/min: A/B = 95:5 isocratic 0.2 min, 95:5 to 
5:95 in 2.3 min, 5:95 isocratic 0.5 min, 5:95 to 95:5 in 0.01 min, 95:5 
isocratic 0.49 min. Method 2 @0.2 mL/min: A/B = 95:5 isocratic 0.5 min, 
95:5 to 5:95 in 10 min, 5:95 isocratic 0.49 min, 5:95 to 95:5 in 0.01 min. 
Stock solutions (100 mM) were prepared in DMSO diluted to 5 µM in water. 
General method for the synthesis of 2a-d. Compound 1 (1 eq.) was pre-
stirred with K2CO3 (1.5 eq.) in DMF or MeCN (20 mL/mmol) before adding 
the corresponding alkyl halide (1.2 eq.). Reactions were then stirred at 
ambient temperature overnight or heated under microwave irradiation for 
2 h at 120 ºC. Solvent was removed under reduced pressure and the crude 
prodrugs purified by semi-preparative TLC. 
Synthesis and characterization of 2c. 38 mg scale, MeCN, µw, purified 
4% MeOH/ CH2Cl2 to yield a yellow solid (23 mg, 39%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.07 (d, J = 9.2 Hz, 1H), 7.68 (d, J = 2.7 Hz, 1H), 7.53 (dd, J 
= 9.2, 2.7 Hz, 1H), 7.41 (t, J = 8.4 Hz, 1H), 7.29 (s, 1H), 6.87 (d, J = 8.4 
Hz, 2H), 6.49 (s, 1H), 5.44 (d, J = 1.4 Hz, 2H), 5.33 (s, 2H), 5.26 (s, 2H), 
4.88 (d, J = 2.4 Hz, 4H), 3.56 (t, J = 2.4 Hz, 2H), 3.24 (q, J = 7.3, 2H), 1.88 
(m,  2H), 1.33 (t, J = 7.4 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (126 
MHz, DMSO-d6) δ 173.0, 158.4, 157.6, 156.4, 150.5, 150.0, 146.8, 145.1, 
144.5, 131.9, 130.9, 130.3, 128.8, 128.3, 123.1, 118.6, 113.4, 106.8, 105.1, 
96.5, 79.6, 78.9, 72.9, 65.7, 56.7, 50.0, 30.7, 22.8, 14.0, 8.2; HRMS (ESI+) 
m/z [M+H]+ calcd for C35H31N2O7: 591.2126 found: 591.2149. Purity: 95% 
(UPLC, method 2). 
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